Recordati investor relations material

Recordati Industria Chimica e Farmaceutica S.p.A., engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. It operates through three segments: Ethical Division, Orphan Drugs Division, and Others. The Ethical Division offers a range of branded prescription products active in therapeutic areas comprising products for cardiovascular system disorders; respiratory system diseases; digestive and metabolism therapies; anti-infectives; hormones and synthetic substitutes; central nervous system disorders; and oncology drugs.The Orphan Drugs Division offers Cerliponase Alfa for treatment of neuronal ceroid lipofuscinoses type 2 (CLN2), a neurodegenerative disease; Laronidase for treatment of mucopolysaccharidosis I, an enzyme deficiency that causes progressive damage to various parts of body.